As recently as 2021, German pharmaceutical company Boehringer Ingelheim opened a new biotech production facility in the Austrian capital, committing to a EUR 700 million investment that also generated 500 new jobs. And 2022 brought a fresh round of investment from the global giant when the groundbreaking ceremony for a new research building took place earlier in July. In all, EUR 60 million will be poured into expanding its cancer research activities in Vienna. Around 150 employees will work at the centre in future.
Takeda: Japanese Investment in Vienna
Boehringer Ingelheim is not the only company currently making major investments in the Austrian capital. Japanese pharmaceutical company Takeda – with 4,500 employees, the single largest pharmaceutical employer in Austria – is also expanding its Vienna operations after decades in the country. A new EUR 120 million building, scheduled for completion by 2025, will serve as a research and development centre for biotech drugs. Around 250 researchers will work on groundbreaking new drugs at the facility once it is up and running. Located in Seestadt Aspern in Vienna’s 22nd district, the building will be among a new crop of additions to this special part of the city, which is fast becoming a centre for the life sciences in its own right.
Life Science Central
Of the nearly 1,000 life science companies and institutions in Austria – representing various scientific fields including biotech, medical technology and pharmaceuticals – almost half are located in Vienna. Together they employ around 41,000 people, generating about EUR 13.3 billion for the Viennese economy in 2020. One of the key factors behind their decision to settle in the city is the overall attractiveness of the location: famously, the Austrian capital is a concentrated centre of expertise – and young talents. Over 42,000 students and more than 8,000 publications in peer-reviewed journals attest to the strong track record of Vienna’s life sciences sector. This fuels a virtuous circle: most of the 20 global market leaders have a strategic presence in the Vienna region. And Vienna’s life science industry has an enormous capacity for innovation, with around 40 per cent of life science companies carrying out research and development or manufacturing their products in the city. Together, these companies invested around EUR 850 million in research and development alone in 2020.
Vienna – Promoting and Supporting Life Sciences
None of this came about by chance: this enduring success story was made possible thanks to the consistent backing of the authorities. Today, numerous sources of support are available: regional clusters such as LISAvienna – a joint initiative of the Vienna Business Agency and the Austria Wirtschaftsservice (aws) to promote the life science industry in the capital – are a vital source of support for companies. Set up in 2002, LISAvienna has seen witnessed various successes in its 20-year history. In addition to welcoming countless companies that have relocated, between ten and 20 new life science ventures are founded in Vienna every year. Among them are specialist start-ups focusing on various innovative projects ranging from drug development and digital health applications to in vitro diagnostics and implantable medical devices. Time and again, LISAvienna has proven to be a key partner to all of these ventures, providing important guidance and support as it continues to add to Vienna’s strengths as a location for the life sciences.
Find out more about Vienna here.